Bray Capital Advisors Acquires Shares of 43,290 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Bray Capital Advisors acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 43,290 shares of the biotechnology company’s stock, valued at approximately $320,000.

Several other institutional investors have also bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at $12,927,000. Principal Financial Group Inc. raised its stake in shares of Iovance Biotherapeutics by 59.0% in the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after acquiring an additional 1,496,941 shares during the period. State Street Corp raised its stake in shares of Iovance Biotherapeutics by 4.6% in the third quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company’s stock valued at $123,967,000 after acquiring an additional 576,801 shares during the period. Barclays PLC raised its stake in shares of Iovance Biotherapeutics by 118.8% in the third quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after acquiring an additional 328,284 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Iovance Biotherapeutics by 399.4% in the third quarter. Victory Capital Management Inc. now owns 144,280 shares of the biotechnology company’s stock valued at $1,355,000 after acquiring an additional 115,387 shares during the period. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

NASDAQ IOVA opened at $5.61 on Friday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -3.77 and a beta of 0.53. The company’s 50-day simple moving average is $6.48 and its two-hundred day simple moving average is $8.71. Iovance Biotherapeutics, Inc. has a one year low of $5.05 and a one year high of $18.33.

Wall Street Analyst Weigh In

IOVA has been the topic of several recent analyst reports. UBS Group initiated coverage on shares of Iovance Biotherapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $17.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. Finally, Piper Sandler reduced their price target on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating on the stock in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Iovance Biotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $21.07.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.